Table 1.
Development in vitro and in vivo (morula/blastocyst transfer) of SCNT-derived embryos treated with HDAC inhibitors
| HDAC inhibitor | Inhibitor concentration (nM) | No. of embryos cultured | No. of two-cell embryos at 24 h (%) | No. of four-cell embryos at 48 h (% per 2 cells) | No. of morula/blast at 72 h (% per 2 cells) | No. of embryos transferred (no. of recipients) | No. of implantations (%) | No. of cloned offspring (%) | No. of placentas only (%) |
|---|---|---|---|---|---|---|---|---|---|
| Control | – | 530 | 484 (91.3) | 382 (78.9) | 271 (56.0) | 210 (14) | 83 (39.5) | 0 (0) | 3 (1.4) |
| TSA | 5 | 64 | 49 (76.5)* | 45 (91.8)* | 32 (65.3) | 15 (1) | 6 (40.0) | 1 (6.7) | 0 (0) |
| Ky-2 | 100 | 63 | 52 (82.5)* | 45 (86.5) | 31 (59.6) | 31 (2) | 7 (22.6)* | 1 (3.2) | 1 (3.2) |
| 10 | 67 | 62 (92.5) | 57 (91.9)* | 38 (61.3) | 38 (2) | 18 (47.4) | 1 (2.6) | 0 (0) | |
| Ky-9 | 1600 | 69 | 57 (82.6)* | 44 (77.2) | 28 (49.1) | 28 (2) | 19 (67.9)* | 2 (7.1)* | 3 (10.7)* |
| 32 | 66 | 60 (90.9) | 50 (83.3) | 35 (58.3) | 25 (2) | 10 (40.0) | 0 (0) | 1 (4.0) | |
| Ky-29 | 2000 | 61 | 54 (88.5) | 51 (94.4)* | 37 (68.5) | 37 (2) | 21 (56.8)* | 1 (2.7) | 4 (10.8)* |
| 400 | 164 | 155 (94.5) | 132 (85.2) | 109 (70.3)* | 88 (5) | 29 (33.0) | 4 (4.5)* | 1 (1.1) | |
| Ky-72 | 1600 | 57 | 47 (82.5)* | 38 (80.9) | 28 (59.6) | 28 (2) | 18 (64.3)* | 2 (7.1)* | 3 (10.7)* |
| Ky-309 | 100 | 69 | 58 (84.0)* | 27 (46.6)* | 6 (10.3)* | 6 (2) | 4 (66.7)* | 1 (16.7)* | 1 (16.7) |
| 5 | 113 | 106 (93.8) | 89 (84.0) | 61 (57.5) | 21 (1) | 4 (19.0)* | 0 (0) | 0 (0) | |
| FK228 | 20 | 67 | 63 (94.0) | 2 (3.2)* | 0 (0)* | N.D. | N.D. | N.D. | N.D. |
* P < 0.05 (vs. control, Fisher exact probability test).